PARP inhibitors work in BRCA-mutant cancers, but resistance is common. Buckley-Benbow et al. show loss of CHTF18-RFC2/5 sensitizes cells via replicative gaps (not recombination defects), and isn’t rescued by 53BP1 loss—highlighting new therapeutic targets. academic.oup.com/narcancer/ar...
Testicular germ cell cancer risk is rising, with disproportionate impact on Hispanic men. New NAR Cancer study of Mexican patients found 7 genes and 3 new genetic variants linked to risk. Inclusive research promotes fair, effective precision medicine. #HealthEquity academic.oup.com/narcancer/ar...
Kavalipati, Aponte, et al. reveal actionable ways to overcome CDK4/6 resistance in HR+ breast cancer — a step toward smarter combination therapies and better patient outcomes. New in NAR Cancer: academic.oup.com/narcancer/ar...
Bill Dynan - NAR Cancer Editor
How does c-MYC overexpression drive transcriptional rewiring in cancer? Sundaram et al report a plausible mechanism involving co-option of TRE/AP1 sites, mainly at enhancers, rising with MYC levels and linked to repression. academic.oup.com/narcancer/ar...
Can SMC5/6 status help guide precision cancer therapy? A new NAR Cancer study links deleterious SMC5/6 variants to tumor mutational burden and immunotherapy responses, driven via POLE dysfunction and mismatch repair deficiency.https://academic.oup.com/narcancer/article/8/2/zcag012/8688771
Few cancer driver mutations have been identified in promoters, maybe for technical reasons. New assay targets >3,000 promoters — hits in CDK4, SMAD3, and GATA3 in breast cancer provide promising leads for functional follow-up. academic.oup.com/narcancer/ar... #CancerGenomics #NonCoding #Promoters
NAR Cancer presents a curated collection of 17 articles on how advances in understanding the DNA damage response are reshaping cancer therapy. Explore the collection and read the editorial from guest editors Li Lan and Elise Fouquerel. New targets and new tools. academic.oup.com/narcancer/pa...
HSF1 drives cancer stress resilience but is hard to target—clever screen identifies spliceosome helicase DHX8 as a druggable regulator of HSF1 splicing→HSF1 program gone, cancer loses stress defenses. Editor's Choice in NAR Cancer. #PrecisionOncology #Spliceosome academic.oup.com/narcancer/ar...
Introducing IGIS, a versatile, scalable platorm to investigate synthetic lethal relationships between cancer therapeutic targets. Haracska et al. describe the platform and validate it by investigation of BRCA1–RAD18 interplay. New in NAR Cancer. academic.oup.com/narcancer/ar...
Terrific on-line seminar - Feb 19 noon EST. Kyungjae Myung, Recent NAR Cancer author, now Director of IBS Center at Ulsan National institute, Korea. "Investigation of genomic integrity & translation for potential clinical applications." Columbia Social DNAing: columbiacuimc.zoom.us/webinar/regi...
Abstract. The use of PARP inhibitors (PARPi) has profoundly changed the treatment of BRCA1/BRCA2-mutated cancers. Despite this, acquired resistance to PARP
academic.oup.com
Abstract. Somatic mutations in protein-coding genes and noncoding regulatory regions are the major drivers of cancer. Only a relatively small number of som
Abstract. Testicular germ cell tumors (TGCT) are highly heritable malignancies that display increasing incidence worldwide, with rising mortality rates par
Abstract. The transcription factor c-MYC (MYC) is deregulated in ~70% of human cancers. Through de novo motif discovery analysis on published MYC ChIP-seq
Abstract. The structural maintenance of chromosomes (SMC) 5/6 complex is conserved and essential for mammalian development. SMC5/6 germline variants in cel
Abstract. Synthetic lethality offers opportunities to identify therapeutic targets for cancer research, facilitating the development of targeted tumour the
